Dr. David E. Schultz II, M.D.
Family Medicine (Family Medicine Physician)
1231 Washington Sq
Evansville, IN 47715
Who else practices at this address →
Vanderburgh County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 704
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: Indiana University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
IN license 01050928A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Deaconess Hospital Inc Evansville, IN
- Ascension St Vincent Evansville Evansville, IN
- Deaconess Henderson Hospital Henderson, KY
- Gibson General Hospital Princeton, IN
- The Women's Hospital Newburgh, IN
Medical groups
- Deaconess Hospital, Inc. (415 clinicians)
- Easter Seals Rehabilitation Center Inc (42 clinicians)
- Evansville Primary Care LLC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 704
- Services billed
- 3,644
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 619 | 300 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 366 | 177 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 262 | 158 |
| Established patient office or other outpatient visit, 20-29 minutes | 254 | 174 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 209 | 209 |
| Injection, dexamethasone sodium phosphate, 1 mg | 200 | 24 |
| Hemoglobin a1c level | 186 | 111 |
| Hospital discharge day management, 30 minutes or less | 132 | 99 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 126 | 101 |
| Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | 95 | 77 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 36 companies reported 222 payments worth $3,342 in total to this clinician.
| AbbVie Inc. | $499 |
|---|---|
| Vanda Pharmaceuticals Inc. | $235 |
| Pfizer Inc. | $225 |
| Lundbeck LLC | $203 |
| Novo Nordisk Inc | $175 |
| Bayer HealthCare Pharmaceuticals Inc. | $172 |
| Amgen Inc. | $156 |
| Merck Sharp & Dohme LLC | $155 |
| Food and Beverage | $3,342 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 2 companies. The companies reported $466,782 in research payments for these studies, mostly to the institutions running them.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clini…
AstraZeneca Pharmaceuticals LP - A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Eli Lilly and Company · Active, not recruiting · NCT06037252 - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Eli Lilly and Company · Active, not recruiting · NCT05433584 - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
Eli Lilly and Company · Completed · NCT05260021
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.